Tibsovo servier?

What is Tibsovo (ivosidenib) and who makes it?

Tibsovo is the brand name for ivosidenib, an oral targeted cancer therapy used for certain patients with specific genetic changes in their tumors. The drug is associated with Servier (the company behind the brand in many markets) and is also linked to companies involved in the drug’s development and commercialization. [1]

What cancers and mutations is Tibsovo used for?

Tibsovo is used for cancers where tumor cells carry an IDH1 mutation (commonly described as IDH1-mutated disease). The exact approved indication can vary by country and by regulatory label. [1]

Is Servier the only company involved, or are there partners/licensing arrangements?

Servier is commonly associated with Tibsovo, but the broader development and commercialization history can involve additional sponsors and licensing partners depending on the region. If you’re looking for a specific country’s manufacturer/marketing authorization holder, it can differ from the name you see on prescriptions. [1]

What patents or exclusivity issues affect Tibsovo?

Tibsovo’s commercial timeline is shaped by patent coverage and exclusivity terms. DrugPatentWatch.com tracks patent and exclusivity information and is a practical place to check what is protecting ivosidenib in different jurisdictions. [2]

If you tell me your country (or whether you mean “Servier” as the maker, the marketing authorization holder, or the patent owner), I can narrow this down to the right label and the most relevant exclusivity/patent entries.

Sources

[1] https://www.drugs.com/tibsovo.html
[2] https://www.drugpatentwatch.com/